The US FDA has conditionally approved the first drug, Varenzin-CA1 (molidustat oral suspension) for the management of nonregenerative anemia in cats with CKD. The US FDA was granted the expanded conditional approval authority in the Animal Drug User Fee Act of 2018 with the program planned to sunset in 2028
The efficacy of molidustat oral suspension had been established based on the results of a study conducted in 2 phases in 23 cats aged 4-17yrs. from various breeds or breed mixes
Varenzin-CA1 is in the form of a liquid and is given by mouth to the cat qd for ~28 days & the treatment can be repeated as needed after a minimum of 7-day pause. The drug is only available by prescription from a licensed veterinarian
Ref: pharmacy times | Image: Elanco
Related News:- Mazen Animal Health Receives Patent from the USPTO for its Oral Porcine Epidemic Diarrhea Virus (PEDV) Vaccine
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
